Relieves bronchospasm. ANDA 207046, held by Rising. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 207046 (Albuterol Sulfate), held by Rising, was first approved by FDA on Jun 29, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2018 | Original application | Approved | None posted |
| Albuterol SulfateEQ 2MG BASE · tablet;oral | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 4MG BASE · tablet;oral | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters